Literature DB >> 9927496

The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations.

A K Vaishnaw1, J R Orlinick, J L Chu, P H Krammer, M V Chao, K B Elkon.   

Abstract

Heterozygous mutations of the receptor CD95 (Fas/Apo-1) are associated with defective lymphocyte apoptosis and a clinical disease characterized by lymphadenopathy, splenomegaly, and systemic autoimmunity. From our cohort of 11 families, we studied eight patients to define the mechanisms responsible for defective CD95-mediated apoptosis. Mutations in and around the death domain of CD95 had a dominant-negative effect that was explained by interference with the recruitment of the signal adapter protein, FADD, to the death domain. The intracellular domain (ICD) mutations were associated with a highly penetrant Canale-Smith syndrome (CSS) phenotype and an autosomal dominant inheritance pattern. In contrast, mutations affecting the CD95 extracellular domain (ECD) resulted in failure of extracellular expression of the mutant protein or impaired binding to CD95 ligand. They did not have a dominant-negative effect. In each of the families with an ECD mutation, only a single individual was affected. These observations were consistent with differing mechanisms of action and modes of inheritance of ICD and ECD mutations, suggesting that individuals with an ECD mutation may require additional defect(s) for expression of CSS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9927496      PMCID: PMC407903          DOI: 10.1172/JCI5121

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  A thermodynamic scale for the helix-forming tendencies of the commonly occurring amino acids.

Authors:  K T O'Neil; W F DeGrado
Journal:  Science       Date:  1990-11-02       Impact factor: 47.728

2.  Monoclonal antibody-mediated tumor regression by induction of apoptosis.

Authors:  B C Trauth; C Klas; A M Peters; S Matzku; P Möller; W Falk; K M Debatin; P H Krammer
Journal:  Science       Date:  1989-07-21       Impact factor: 47.728

3.  Chronic lymphadenopathy simulating malignant lymphoma.

Authors:  V C Canale; C H Smith
Journal:  J Pediatr       Date:  1967-06       Impact factor: 4.406

4.  Hereditary splenomegaly with hypersplenism.

Authors:  L M Rao; N T Shahidi; J M Opitz
Journal:  Clin Genet       Date:  1974       Impact factor: 4.438

5.  Genotype-restricted lymphoproliferation in autoimmune lpr mice.

Authors:  A Matsuzawa; M Kimura; T Muraiso; R Kominami; T Katagiri
Journal:  Eur J Immunol       Date:  1991-06       Impact factor: 5.532

6.  Large differences in the helix propensities of alanine and glycine.

Authors:  A Chakrabartty; J A Schellman; R L Baldwin
Journal:  Nature       Date:  1991-06-13       Impact factor: 49.962

7.  A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease.

Authors:  M C Sneller; S E Straus; E S Jaffe; J S Jaffe; T A Fleisher; M Stetler-Stevenson; W Strober
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 8.  Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease.

Authors:  P L Cohen; R A Eisenberg
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

9.  Fas transduces activation signals in normal human T lymphocytes.

Authors:  M R Alderson; R J Armitage; E Maraskovsky; T W Tough; E Roux; K Schooley; F Ramsdell; D H Lynch
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

10.  Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase.

Authors:  M G Cifone; R De Maria; P Roncaioli; M R Rippo; M Azuma; L L Lanier; A Santoni; R Testi
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

View more
  33 in total

1.  Apoptosis induced by the nuclear death domain protein p84N5 is inhibited by association with Rb protein.

Authors:  J Doostzadeh-Cizeron; R Evans; S Yin; D W Goodrich
Journal:  Mol Biol Cell       Date:  1999-10       Impact factor: 4.138

2.  Contribution of apoptosis and apoptosis-related proteins to the malformation of the primitive intrahepatic biliary system in Meckel syndrome.

Authors:  C Sergi; P Kahl; H F Otto
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

3.  Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma.

Authors:  Lijun Shen; Anthony C T Liang; Liwei Lu; Wing Yan Au; Yok-Lam Kwong; Raymond H S Liang; Gopesh Srivastava
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

4.  Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation.

Authors:  Aude Magerus-Chatinet; Bénédicte Neven; Marie-Claude Stolzenberg; Cécile Daussy; Peter D Arkwright; Nina Lanzarotti; Catherine Schaffner; Sophie Cluet-Dennetiere; Filomeen Haerynck; Gérard Michel; Christine Bole-Feysot; Mohammed Zarhrate; Isabelle Radford-Weiss; Serge P Romana; Capucine Picard; Alain Fischer; Frédéric Rieux-Laucat
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

5.  Deletion of PTEN and BMPR1A on chromosome 10q23 is not always associated with juvenile polyposis of infancy.

Authors:  Leonardo Salviati; Mariagrazia Patricelli; Graziella Guariso; Giacomo Carlo Sturniolo; Rita Alaggio; Franca Bernardi; Orsetta Zuffardi; Romano Tenconi
Journal:  Am J Hum Genet       Date:  2006-09       Impact factor: 11.025

Review 6.  Death receptors and caspases: role in lymphocyte proliferation, cell death, and autoimmunity.

Authors:  Sabine Adam-Klages; Dieter Adam; Ottmar Janssen; Dieter Kabelitz
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome.

Authors:  Hye Sun Kuehn; Iusta Caminha; Julie E Niemela; V Koneti Rao; Joie Davis; Thomas A Fleisher; João B Oliveira
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

8.  Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.

Authors:  Kennichi C Dowdell; Julie E Niemela; Susan Price; Joie Davis; Ronald L Hornung; João Bosco Oliveira; Jennifer M Puck; Elaine S Jaffe; Stefania Pittaluga; Jeffrey I Cohen; Thomas A Fleisher; V Koneti Rao
Journal:  Blood       Date:  2010-04-01       Impact factor: 22.113

9.  Detection, epitope-mapping and function of anti-Fas autoantibody in patients with silicosis.

Authors:  Akiko Takata-Tomokuni; Ayako Ueki; Mieko Shiwa; Yumika Isozaki; Tamayo Hatayama; Hironobu Katsuyama; Fuminori Hyodoh; Wataru Fujimoto; Hiroaki Ueki; Masayasu Kusaka; Hisashi Arikuni; Takemi Otsuki
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

Review 10.  Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS).

Authors:  David T Teachey; Alix E Seif; Stephan A Grupp
Journal:  Br J Haematol       Date:  2009-11-23       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.